Home › Funds › Bellevue Group AG › ABT

Bellevue Group AG position in ABT

ABBOTT LABORATORIES · Health Care

Bellevue Group AG reported holding 947,115 shares of ABT (ABBOTT LABORATORIES) in its Q2 2026 13F filing — a position valued at US$85.9M, representing 1.81% of its reported portfolio and ranking #19 among its reported holdings. Bellevue Group AG has disclosed ABT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)947.12K sh
Reported value held$85.94M
Portfolio Weight1.81%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Bellevue Group AG's ABT position evolved

Bellevue Group AG first disclosed a stake in ABT in Q3 2023 at 1,560,968 shares (US$151.2M). The position peaked in Q2 2025 at 1,564,022 shares, worth US$212.7M. Across 12 filings, Bellevue Group AG increased the stake 3 time(s), trimmed it 8 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 947,115 shares valued at US$85.9M — a reduction of -204,520 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.56M $151.18M New
Q4 2023 1.54M $169.03M Reduce
Q1 2024 1.43M $163.01M Reduce
Q2 2024 1.61M $166.90M Add
Q3 2024 1.74M $198.83M Add
Q4 2024 1.69M $191.00M Reduce
Q1 2025 1.56M $206.42M Reduce
Q2 2025 1.56M $212.72M Add
Q3 2025 1.48M $198.04M Reduce
Q4 2025 1.32M $165.00M Reduce
Q1 2026 1.15M $118.24M Reduce
Q2 2026 947.12K $85.94M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 20 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has Bellevue Group AG held ABT?

Bellevue Group AG has disclosed ABT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Bellevue Group AG's current position in ABT?

As of Q2 2026, Bellevue Group AG holds 947.12K shares of ABT (ABBOTT LABORATORIES), valued at $85.94M, representing 1.81% of its reported portfolio and ranking #19.

Has Bellevue Group AG been buying or selling ABT?

In the latest 13F filing (Q2 2026), Bellevue Group AG reduced its position in ABT. The position peaked in Q2 2025 at 1.56M shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 20 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.